Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07585877
Active, not recruiting Not applicable

Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression

NCT07585877 · tracked via the Priya Life Science China tracker
Sponsor
Zhongda Hospital
Phase
Not applicable
Started
2026-01-05
Last updated
2026-07-13

Condition(s) studied

Myopia ProgressingMyopia

Investigational drug(s) / intervention(s)

Branched-Chain Amino Acids (BCAA) Supplementation

Branched-Chain Amino Acids (BCAA) Supplementation: Participants will receive oral branched-chain amino acids (BCAA), including leucine, isoleucine, and valine, as a dietary supplement in addition to standard spectacle correction. The intervention is administered daily for approximately 6 months. The supplement is a commercially available nutritional product obtained via cross-border e-commerce channels and is not intended as a therapeutic drug. The aim is to evaluate the effect of BCAA supplementation on myopia progression and ocular biometric parameters.

Study summary

This study is a randomized controlled trial designed to evaluate whether branched-chain amino acid (BCAA) supplementation can help slow the progression of myopia in young adults.

Eligible participants will be randomly assigned to receive either BCAA supplementation combined with standard spectacle correction or standard spectacle correction with a matching placebo. The intervention period will last approximately six months.

Participants will undergo regular follow-up examinations, including measurements of visual acuity, refractive error, axial length, intraocular pressure, and other ocular parameters. Additional assessments such as ocular imaging (including OCTA), physical examinations, and blood tests will also be performed to evaluate eye health and metabolic indicators.

The main purpose of this study is to investigate whether BCAA supplementation can provide a safe and effective nutritional strategy to slow myopia progression and improve understanding of the relationship between amino acid metabolism and ocular growth.

Eligibility

Sex
ALL
Min age
18 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Healthy university students aged 18-25 years; 2. Spherical equivalent refraction (for eyes without prior corneal refractive surgery): SE ≤ -0.50 D; 3. Corrected visual acuity ≥ 0.8; 4. Corneal curvature 40 D-46 D; 5. Good compliance and ability to cooperate with follow-up and examinations; 6. Willingness and ability to participate in this study and sign the informed consent form. Exclusion Criteria: 1. Strabismus, amblyopia, or other pathological ocular changes; 2. Systemic diseases affecting refractive development and allergic constitution, such as diabetes, metabolic syndrome, etc.; 3. Active eye disease or history of ophthalmic surgery; 4. Use of orthokeratology lenses or other myopia-control interventions within the past 6 months; 5. Use of BCAA-related supplements within the past 6 months, or serum BCAA levels outside the reference range; 6. Considered by the responsible physician to be unable to participate or unable to comply with the study requirements; 7. Abnormal liver or kidney function.

Primary outcome measure(s)

  • Change in axial length — Baseline to 6 months
    Axial length (AL) will be measured in both eyes using optical biometry at baseline, 3 months, and 6 months. The primary outcome is the change in axial length from baseline to 6 months, comparing the BCAA supplementation plus spectacle correction group with the spectacle correction only group.
  • Change in spherical equivalent refractive error — Baseline to 6 months
    Cycloplegic spherical equivalent (SE) will be measured using autorefractometry under cycloplegia at baseline, 3 months, and 6 months. The primary outcome is the change in spherical equivalent refractive error from baseline to 6 months, comparing the BCAA supplementation group with the control group.

Trial sites (1)

FacilityCityRegionStatus
School of Public Health, Southeast University Nanjing Jiangsu

More Zhongda Hospital trials in China

Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001) Active, not recruiting
Personalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability Recruiting
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection Starting soon
Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability Recruiting
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease Starting soon

Other trials for the same condition

A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops Active, not recruiting
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control Active, not recruiting
Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine Starting soon
Spectacle Films Utilising S.T.O.P.® Technology for Slowing Down Myopia Progression in Children Active, not recruiting
Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07585877 on ClinicalTrials.gov ↗ ← All trials in China